CN113499279A - Freeze-dried milk tablet for whitening, repairing and resisting aging and preparation process thereof - Google Patents
Freeze-dried milk tablet for whitening, repairing and resisting aging and preparation process thereof Download PDFInfo
- Publication number
- CN113499279A CN113499279A CN202110671538.5A CN202110671538A CN113499279A CN 113499279 A CN113499279 A CN 113499279A CN 202110671538 A CN202110671538 A CN 202110671538A CN 113499279 A CN113499279 A CN 113499279A
- Authority
- CN
- China
- Prior art keywords
- freeze
- parts
- weight
- whitening
- dried
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 67
- 239000008267 milk Substances 0.000 title claims abstract description 67
- 210000004080 milk Anatomy 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 230000002087 whitening effect Effects 0.000 title claims abstract description 18
- 230000032683 aging Effects 0.000 title abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 32
- 238000011049 filling Methods 0.000 claims abstract description 31
- 238000001035 drying Methods 0.000 claims abstract description 27
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 20
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 17
- 239000003381 stabilizer Substances 0.000 claims abstract description 17
- 230000005059 dormancy Effects 0.000 claims abstract description 16
- 230000002438 mitochondrial effect Effects 0.000 claims abstract description 16
- 239000004530 micro-emulsion Substances 0.000 claims abstract description 15
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract description 14
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract description 14
- 230000003213 activating effect Effects 0.000 claims abstract description 13
- 238000011146 sterile filtration Methods 0.000 claims abstract description 12
- 239000003906 humectant Substances 0.000 claims abstract description 11
- 239000006172 buffering agent Substances 0.000 claims abstract description 7
- 239000000463 material Substances 0.000 claims description 49
- 229920002907 Guar gum Polymers 0.000 claims description 18
- 239000000665 guar gum Substances 0.000 claims description 18
- 235000010417 guar gum Nutrition 0.000 claims description 18
- 229960002154 guar gum Drugs 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 229930195725 Mannitol Natural products 0.000 claims description 12
- 239000000594 mannitol Substances 0.000 claims description 12
- 235000010355 mannitol Nutrition 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000007710 freezing Methods 0.000 claims description 10
- 230000008014 freezing Effects 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 7
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 239000005720 sucrose Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 3
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 3
- 229920002643 polyglutamic acid Polymers 0.000 claims description 3
- 235000011950 custard Nutrition 0.000 claims 3
- 238000004108 freeze drying Methods 0.000 abstract description 21
- 238000005516 engineering process Methods 0.000 abstract description 7
- 241001391944 Commicarpus scandens Species 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 50
- 239000000047 product Substances 0.000 description 34
- 238000000034 method Methods 0.000 description 24
- 230000037303 wrinkles Effects 0.000 description 12
- 230000008569 process Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 238000007619 statistical method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000037393 skin firmness Effects 0.000 description 6
- 238000002372 labelling Methods 0.000 description 5
- 238000012353 t test Methods 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010050637 Skin tightness Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000011016 integrity testing Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000006076 specific stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/737—Galactomannans, e.g. guar; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/805—Corresponding aspects not provided for by any of codes A61K2800/81 - A61K2800/95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/84—Products or compounds obtained by lyophilisation, freeze-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of skin care, in particular to a freeze-dried small milk tablet for whitening, repairing and resisting aging and a preparation process thereof. The invention provides a skin-whitening, repairing and anti-aging freeze-dried milk tablet, which is prepared from the following raw materials, by weight, 6-10 parts of an excipient, 0.1-2 parts of a stabilizer, 0.06-0.2 part of a buffering agent, 0.1-2 parts of a humectant, 1-5 parts of maltose, 0.1-2 parts of a nano microemulsion and 0.1-2 parts of a mitochondrial activating factor. Preparing raw materials; preparing a mould; burdening and filtering; precise sterile filtration; filling; dormancy of frozen organisms; drying at low temperature; and (4) demolding to prepare the freeze-dried small milk tablets. The shape of the milk tablet can not be made by the freeze-drying technology in the prior art, the made milk tablet is easy to break, the shape of the complete milk tablet can be made by the invention, and the milk tablet made by the technology is very easy to dissolve in a solvent.
Description
Technical Field
The invention relates to the technical field of skin care, in particular to a freeze-dried small milk tablet for whitening, repairing and resisting aging and a preparation process thereof.
Background
The skin is a barrier to the penetration of various molecules, and can prevent the invasion of external harmful substances or unwanted substances, and as people age and people are more irritated to the environment, the skin of people is aged, so that the phenomena of dark yellow skin, no luster and more wrinkles occur. With the increase of the aging phenomenon of the skin of people, various cosmetics on the market are also diversified, and more cosmetics are skin care products in the forms of emulsion and cream, which contain moisture and are short in storage time, and in order to prolong the storage time, preservatives are often added into the skin care products, but have a certain stimulation effect on the skin of people and cannot be used for a long time.
With the attention of people on skin care, skin care is carried out anytime and anywhere, and in order to prepare a skin care product which is convenient to carry and free of preservative, the problems are solved by the appearance of a freeze-drying technology, but the existing freeze-dried skin care product prepared by the freeze-drying technology contains more freeze-dried powder, so that in the process of preparing the freeze-dried powder, the retention of active ingredients in the components is less, the skin care effect of the freeze-dried powder is reduced, the skin care product is rarely prepared into a milk tablet shape, and the shape of the prepared freeze-dried milk tablet is incomplete mainly because the raw materials and the process are immature.
Disclosure of Invention
In order to solve the technical problems, the first aspect of the invention provides a freeze-dried milk tablet for whitening, repairing and anti-aging, which is prepared from 6-10 parts by weight of excipient, 0.1-2 parts by weight of stabilizer, 0.06-0.2 part by weight of buffer, 0.1-2 parts by weight of humectant, 1-5 parts by weight of maltose, 0.1-2 parts by weight of nano microemulsion and 0.1-2 parts by weight of mitochondrial activation factor.
In a preferred embodiment of the present invention, the excipient is at least one selected from mannitol, glycine, glucose, and sucrose.
As a preferred technical solution of the present invention, the stabilizer is at least one selected from glycine, guar gum, sucrose, lactose, and dextran.
As a preferable technical scheme of the invention, the weight ratio of the stabilizer to the excipient is (0.5-8): 40.
in a preferred embodiment of the present invention, the buffer is at least one selected from the group consisting of acetic acid, succinic acid, glutamic acid, glutaric acid, disodium hydrogen phosphate, and citric acid.
In a preferred embodiment of the present invention, the humectant is at least one selected from the group consisting of 1, 3-butanediol, 1, 2-hexanediol, caprylyl glycol, glycerin, polyglutamic acid, sodium hyaluronate, and collagen.
The second aspect of the invention provides a preparation process of a freeze-dried milk tablet for whitening, repairing and anti-aging, which comprises the following preparation steps:
(1) preparation of raw materials: accurately weighing the raw materials of the freeze-dried small milk tablets according to the parts by weight for later use;
(2) preparation of a mold: arranging the mold, washing the mold with pure water, sterilizing and drying to obtain a precise mold;
(3) material preparation and filtration: mixing the freeze-dried small milk tablets with pure water, and filtering to obtain a mixed material A;
(4) precise sterile filtration: performing precise sterile filtration on the mixed material A to obtain a mixed material B;
(5) filling: filling the mixed material B by using a precision mold to obtain a filling material A;
(6) frozen organism dormancy: carrying out frozen biological dormancy treatment on the filling material A;
(7) and (3) low-temperature drying: drying the filling material A after the frozen organisms are dormant at low temperature;
(8) demolding: and demolding the filling material A dried at the low temperature to obtain the freeze-dried small milk tablets.
As a preferable technical scheme of the invention, the batching and the filtering are divided into two steps, wherein the first step is coarse batching and filtering, and the second step is fine batching and filtering.
As a preferred technical scheme of the invention, a precision flat filter is adopted to carry out precision sterile filtration on the mixed material.
In a preferred embodiment of the present invention, the freezing mode in which the frozen organism is dormant is an extremely rapid freezing mode.
Has the advantages that:
1. in the system, the mitochondrion activation factor can well permeate the skin by utilizing the transdermal permeability of the specific nano microemulsion, the whitening effect is good in a short time after the freeze-dried small milk tablet is used, deep cells of the skin can be activated, repaired and renewed, and long-term anti-aging and whitening effects can be achieved;
2. in the prior art, the shape of the milk tablet cannot be made by a freeze-drying technology, the made milk tablet is easy to break, the shape of the complete milk tablet can be made by the invention, and the milk tablet made by the technology is very easy to dissolve in a solvent;
3. under the action of specific components such as an excipient, a stabilizer, a buffering agent and the like, the composition has good activation effect on the skin by the mitochondrial agonist and the nano microemulsion;
4. through a specific freezing biological dormancy step in the system, the active ingredients of the mitochondrial activating factor and the humectant can be well frozen for fresh keeping, and the survival of the active ingredients is ensured.
Detailed Description
The invention will be further understood by reference to the following detailed description of preferred embodiments of the invention and the examples included therein. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. To the extent that a definition of a particular term disclosed in the prior art is inconsistent with any definition provided in the present disclosure, the definition of the term provided in the present disclosure controls.
As used herein, a feature that does not define a singular or plural form is also intended to include a plural form of the feature unless the context clearly indicates otherwise. It will be further understood that the term "prepared from …," as used herein, is synonymous with "comprising," including, "comprising," "having," "including," and/or "containing," when used in this specification means that the recited composition, step, method, article, or device is present, but does not preclude the presence or addition of one or more other compositions, steps, methods, articles, or devices. Furthermore, the use of "preferred," "preferably," "more preferred," etc., when describing embodiments of the present invention, is meant to refer to embodiments of the invention that may provide certain benefits, under certain circumstances. However, other embodiments may be preferred, under the same or other circumstances. In addition, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, nor is it intended to exclude other embodiments from the scope of the invention.
In order to solve the technical problems, the first aspect of the invention provides a freeze-dried milk tablet for whitening, repairing and anti-aging, which is prepared from 6-10 parts by weight of excipient, 0.1-2 parts by weight of stabilizer, 0.06-0.2 part by weight of buffer, 0.1-2 parts by weight of humectant, 1-5 parts by weight of maltose, 0.1-2 parts by weight of nano microemulsion and 0.1-2 parts by weight of mitochondrial activation factor.
In one embodiment, the freeze-dried milk tablet is prepared from 7-9 parts by weight of excipient, 0.8-1.6 parts by weight of stabilizer, 0.01-0.15 part by weight of buffering agent, 1-1.8 parts by weight of humectant, 2-4 parts by weight of maltose, 1-1.5 parts by weight of nano microemulsion and 0.5-1 part by weight of mitochondrial activating factor.
In one embodiment, the freeze-dried milk tablet is prepared from 8 parts of excipient, 1.2 parts of stabilizer, 0.12 part of buffering agent, 1.5 parts of humectant, 3 parts of maltose, 1.3 parts of nano microemulsion and 0.8 part of mitochondrial activating factor by weight.
Excipient
In order to enable the active ingredient to be present in the system, a certain amount of excipient is selected, which in one embodiment is selected from at least one of mannitol, glycine, glucose, sucrose.
In order to achieve a better shaping of the freeze-dried creamer tablet, in a preferred embodiment the excipient is mannitol with a CAS number 1707-77-3.
Stabilizer
In order to allow good synergy between the excipient and the stabilizer in the system, in one embodiment, the weight ratio of the stabilizer to the excipient is (1-9): 40, preferably (2-8): 40; more preferably 6: 40.
to increase the stability of the system, in one embodiment, the stabilizer is selected from at least one of glycine, guar gum, sucrose, lactose, dextran.
In order to ensure the integrity and smoothness of the freeze-dried creamer, in a preferred embodiment the stabilizer is guar gum with a CAS number of 9000-30-0.
At present, no one in the market has the shape of the milk slices made by the freeze-drying technology, and the milk slices made by some experiments are easy to break, mainly because the raw materials and the process conditions are not well controlled. In the invention, the applicant finds that the freeze-dried small milk tablets prepared by selecting guar gum as a stabilizer can be well formed and are not easy to break through a large amount of researches. Probably because the application selects the specific stabilizer guar gum, the guar gum mainly consists of polysaccharide, the guar gum can well interact with mannitol and maltose, and the stability of the system is increased, and the invention also researches and discovers that the proportion of the guar gum and the mannitol needs to be controlled to ensure that the integrity of the freeze-dried small milk tablet is better, probably because the stabilizing effect cannot be well exerted when the amount of the guar gum is too small, but when the amount of the guar gum is too large, the viscosity of the system is increased, and the shearing force in the processing process can be more easily acted on the excipient to ensure that the freeze-dried small milk tablet is more easily damaged.
Buffering agent
In order to make the nano-microemulsion, the mitochondrial activating factor, exist more stable in the system, in one embodiment, the buffer is selected from at least one of acetic acid, succinic acid, glutamic acid, glutaric acid, disodium hydrogen phosphate, citric acid.
In a preferred embodiment, the buffer is disodium phosphate having a CAS number of 7558-80-7.
Maltose
In one embodiment, the maltose is purchased at a southern sea color field bee product factory, mountain of fogshan.
The unit structure of maltose is glucose, which can well interact with other components in the system and has good stability, so that the nano microemulsion and the mitochondrial activating factor can stably exist in the system, and the addition of maltose enables the forming effect of the freeze-dried milk tablet to be better, probably because the maltose contains a large amount of dextrin, the system is not easy to crystallize in the freeze-drying process.
Moisture-retaining agent
In order to provide a good moisturizing effect to the freeze-dried milk tablet, in one embodiment, the moisturizing agent is at least one selected from 1, 3-butanediol, 1, 2-hexanediol, caprylyl glycol, glycerin, polyglutamic acid, sodium hyaluronate, and collagen.
In a preferred embodiment, the humectant is sodium hyaluronate.
In one embodiment, the sodium hyaluronate is purchased from donnawa bio-medicine, inc.
Nano microemulsion
In order to allow the active ingredients in the lyophilized milk tablets to act better on the skin, in one embodiment, the nano-microemulsion is purchased from Nexsome H of the giga-honest chemical, ltd, guangzhou.
The nano microemulsion has the advantages of large surface area, low surface tension, patch effect on skin, better penetration effect of active ingredients, faster absorption and more stable system due to synergistic effect with other ingredients in the system.
Mitochondrial activating factor
In one embodiment, the mitochondrial activating factor is purchased from river-south university.
The Forskolin composite essence as the main component of the mitochondrial activating factor can activate the increase of intracellular cyclic adenosine monophosphate (cAMP) level, so that the bioactivity of Stress Activated Protein (SAPK) in cells is inhibited, the biosynthesis of mitochondria in the cells is stimulated, nutrients such as intracellular energy ATP are supplied, the endogenous growth and deep repair and renewal of skin are promoted, and the anti-aging effect is finally achieved.
The second aspect of the invention provides a preparation process of a freeze-dried milk tablet for whitening, repairing and anti-aging, which comprises the following preparation steps:
(1) preparation of raw materials: accurately weighing the raw materials of the freeze-dried small milk tablets according to the parts by weight for later use;
(2) preparation of a mold: arranging the mold, washing the mold with pure water, sterilizing and drying to obtain a precise mold;
(3) material preparation and filtration: mixing the freeze-dried small milk tablets with pure water, and filtering to obtain a mixed material A;
(4) precise sterile filtration: performing precise sterile filtration on the mixed material A to obtain a mixed material B;
(5) filling: filling the mixed material B by using a precision mold to obtain a filling material A;
(6) frozen organism dormancy: carrying out frozen biological dormancy treatment on the filling material A;
(7) and (3) low-temperature drying: drying the filling material A after the frozen organisms are dormant at low temperature;
(8) demolding: and demolding the filling material A dried at the low temperature to obtain the freeze-dried small milk tablets.
And sealing, packaging, labeling, boxing and warehousing the demolded freeze-dried small milk slices by using the sterilized aluminum film.
Specifically, the batching and filtering are divided into two steps, wherein the first step is coarse batching and filtering, and the second step is fine batching and filtering; more specifically, the process of coarse batching and filtering is as follows: mixing and filtering the raw materials of the freeze-dried small milk tablets by using pure water, wherein the weight ratio of the pure water to the raw materials of the freeze-dried small milk tablets is 100 (15-30); the processes of fine material preparation and filtration are as follows: and filtering the crude ingredients and the filter cake obtained by filtering by using pure water, wherein the weight ratio of the pure water to the raw materials of the freeze-dried small milk tablets is 80 (15-30).
Specifically, a precision flat filter is used for precision sterile filtration of the mixed material, and more specifically, the precision flat filter has a filtration precision of 2 microns.
Specifically, a frozen biological dormancy treatment is carried out by adopting a method of extremely fast freezing; more specifically, filling A is put into a freezing device for freezing; more specifically, the temperature reduction program of the refrigerating device is as follows: cooling to-50 deg.C at 2.5 deg.C/min-5 deg.C/min, and holding at-50 deg.C for 80-120 min.
At present, people pursue portable cosmetics, and the cosmetics are prepared into freeze-dried powder, but the use effect of the freeze-dried powder is poor, some effective components are lost in the preparation process and cannot survive well, and the efficacy of the effective components of the prepared freeze-dried powder is poor.
Through a large number of researches, the applicant finds that the active ingredients of the mitochondrial activating factor and the humectant can be well frozen and preserved through a specific freezing biological dormancy step in the system, so that the survival of the active ingredients is ensured.
Specifically, low-temperature drying is carried out in a freeze-drying box capable of automatically controlling the temperature; more specifically, an automatic temperature control curve of the freeze-drying box is set, the temperature of the freeze-drying box is raised to 0 ℃, and then the temperature is raised to 35 ℃; specifically, the time for low-temperature drying is 16h, and the pressure is 30 pa; more specifically, the temperature rise rate of the later temperature rise to 35 ℃ is 0.1-0.6 ℃/min;
more specifically, the low-temperature drying step is that the filling material A after the frozen organisms are dormant is placed into a freeze-drying box capable of automatically controlling the temperature, the automatic temperature control curve of the freeze-drying box is set, the temperature is raised to 0 ℃, then the temperature is raised to 35 ℃ at the temperature raising rate of 0.4 ℃/min, wherein the time for low-temperature drying is 16 hours, and the pressure is 30 pa.
The research shows that the freeze-drying process has certain influence on the integrity of the freeze-dried small milk slices, the time and the speed of the freeze-dried small milk slices are strictly controlled, the integrity of the freeze-dried small milk slices is influenced when the time and the speed of the drying are too high or too high, probably because when the speed of the low-temperature drying is too high and the time is too short, the moisture in the freeze-dried small milk slices cannot be completely dried, the moisture is sealed by an over-dried part and cannot be volatilized, the forming and the shrinkage are prevented, and when the freeze-drying speed is too low and the time is too long, the freeze-dried small milk slices are completely dried and are at the temperature which is too low, so the smoothness of the surface is reduced.
Specific examples of the present invention are given below, but the present invention is not limited by the examples.
In addition, the starting materials in the present invention are all commercially available unless otherwise specified.
Examples
Example 1
The embodiment 1 of the invention provides a freeze-dried milk tablet for whitening, repairing and anti-aging, which is prepared from the following raw materials, by weight, 8 parts of mannitol, 1.2 parts of guar gum, 0.12 part of disodium hydrogen phosphate, 1.5 parts of sodium hyaluronate, 3 parts of maltose, 1.3 parts of nano microemulsion and 0.8 part of mitochondrial activating factor;
the weight ratio of the guar gum to the mannitol is 6: 40;
the nano microemulsion is purchased from Nexsome H of Jucheng chemical engineering Co., Ltd, Guangzhou; the mitochondrial activating factor was purchased from river-south university.
The preparation process of the freeze-dried milk powder tablets for whitening, repairing and anti-aging comprises the following preparation steps:
(1) preparation of raw materials: accurately weighing the raw materials of the freeze-dried small milk tablets according to the parts by weight for later use; (2) preparation of a mold: arranging the mold, washing the mold with pure water, sterilizing and drying to obtain a precise mold; (3) material preparation and filtration: mixing the freeze-dried small milk tablets with pure water, and filtering to obtain a mixed material A; (4) precise sterile filtration: performing precise sterile filtration on the mixed material A to obtain a mixed material B; (5) filling: filling the mixed material B by using a precision mold to obtain a filling material A; (6) frozen organism dormancy: carrying out frozen biological dormancy treatment on the filling material A; (7) and (3) low-temperature drying: drying the filling material A after the frozen organisms are dormant at low temperature; (8) demolding: and demolding the filling material A dried at the low temperature to obtain the freeze-dried small milk tablets.
The material mixing and filtering are divided into two steps, wherein the first step is coarse material mixing and filtering, and the second step is fine material mixing and filtering; the process of coarse material preparation and filtration is as follows: mixing and filtering the raw materials of the freeze-dried small milk tablets by using pure water, wherein the weight ratio of the pure water to the raw materials of the freeze-dried small milk tablets is 100: 22; the processes of fine material preparation and filtration are as follows: filtering the coarse ingredients and the filter cake obtained by filtering by using pure water, wherein the weight ratio of the pure water to the raw materials of the freeze-dried small milk tablets is 80: 25;
adopt the frozen side of utmost point to send out and freeze biological dormancy processing, freeze filling A in putting into refrigerating plant, wherein, the cooling procedure of freezing the device is: cooling to-50 deg.C at 3.5 deg.C/min, and holding at-50 deg.C for 100 min;
the low-temperature drying is carried out in a freeze-drying box capable of automatically controlling the temperature, and the method comprises the following specific steps: setting an automatic temperature control curve of a freeze-drying box, heating the freeze-drying box to 0 ℃, and then heating the freeze-drying box to 35 ℃; the time for low-temperature drying is 16h, and the pressure is 30 pa; the heating rate of heating to 35 ℃ is 0.35 ℃/min;
the specific steps of low-temperature drying are that the filling material A after the frozen organisms are dormant is placed into a freeze-drying box capable of automatically controlling the temperature, the automatic temperature control curve of the freeze-drying box is set, the temperature is raised to 0 ℃, and then the temperature is raised to 35 ℃ at the temperature raising rate of 0.4 ℃/min, wherein the time for low-temperature drying is 16 hours, and the pressure is 30 pa.
The CAS number for mannitol is 1707-77-3; the CAS number of the guar gum is 9000-30-0; the buffering agent is disodium hydrogen phosphate with CAS number of 7558-80-7; the maltose is purchased from a product factory in the color field bee industry in the south China sea of the Foshan city; sodium hyaluronate was purchased from Dongan Hua biomedical corporation, Inc.
Example 2
The embodiment 2 of the invention provides a skin-whitening, repairing and anti-aging freeze-dried milk tablet, which is implemented in the same way as the embodiment 1, except that mannitol is replaced by chitosan.
Example 3
The embodiment 3 of the invention provides a skin-whitening, repairing and anti-aging freeze-dried small milk tablet, which is the same as the embodiment 1, and is different from the embodiment 1 in that the specific step of low-temperature drying is that the filling material A after the dormancy of frozen organisms is placed into a freeze-drying box capable of automatically controlling the temperature, the automatic temperature control curve of the dry box is set, the temperature is raised to 0 ℃, then the temperature is raised to 35 ℃ at the temperature raising rate of 0.4 ℃/min, wherein the time for low-temperature drying is 10 hours, and the pressure is 30 pa.
Example 4
The embodiment 4 of the invention provides a skin-whitening, repairing and anti-aging freeze-dried small milk tablet, which is the same as the embodiment 1, and is different from the embodiment 1 in that the specific step of low-temperature drying is that the filling material A after the dormancy of frozen organisms is placed into a freeze-drying box capable of automatically controlling the temperature, the automatic temperature control curve of the dry box is set, the temperature is raised to 0 ℃, then the temperature is raised to 35 ℃ at the temperature raising rate of 0.4 ℃/min, wherein the time for low-temperature drying is 5 hours, and the pressure is 30 pa.
Example 5
The embodiment 5 of the invention provides a skin-whitening, repairing and anti-aging freeze-dried yogurt tablet, which is the same as the embodiment 1 in the specific implementation manner, and is characterized in that 0.6 part of guar gum is used, and the weight ratio of the guar gum to mannitol is 3: 40.
example 6
The embodiment 6 of the invention provides a skin-whitening, repairing and anti-aging freeze-dried yogurt tablet, which is the same as the embodiment 1 in the specific implementation manner, and is characterized in that 2 parts of guar gum are used, and the weight ratio of the guar gum to mannitol is 10: 40.
performance testing
1. Skin firmness R0, skin gloss, skin brightness ITA and wrinkle area ratio test
The test method comprises the following steps:
selecting facial skin with uneven, dark and lack of luster; the facial skin meets the canthus wrinkle grade of 2-5; 33 healthy Chinese female subjects with loose facial skin and lack of elasticity, wherein the age range is 25-55 years. The skin firmness R0, skin gloss, skin brightness ITA and wrinkle area ratio were tested before, immediately after, 7 days after continuous use of the test product, 14 days after continuous use of the product, respectively. The evaluation results before and after the product is used are compared by a statistical test method to judge whether the product has statistical difference. Wherein: the measuring instrument of the skin tightness R0 is a skin elasticity tester Cutomer dual MPA580, and the test area is a cheek; the measuring instrument for the skin glossiness is a skin glossiness testing probe Gloymeter GL200, and a testing area is a cheek; the measuring instrument of the skin brightness ITA is a skin color testing probe Colorimeter CL400, and the testing area is a cheek; the measuring instrument for the wrinkle area ratio is a facial image analyzer VISLA-CR, and the test area is a whole face.
And (3) testing conditions are as follows:
the environmental temperature of the test is 20.1-21.2 ℃, and the relative humidity is 42.1-51.0%.
Test sample product:
the freeze-dried milk powder prepared in example 1 was mixed with a serum.
The using method comprises the following steps:
2 times daily, 1 time in the morning and evening.
The statistical method comprises the following steps:
the statistical analysis software was SPSS. If the numerical value is normal distribution, performing statistical analysis by adopting a t test method; if the numerical value is in non-normal distribution, performing statistical analysis by adopting a rank sum test method;
the statistical method adopts two-tail test, and the test level is 0.05.
The safety evaluation adopts a statistical description method to analyze the adverse event degree and the adverse event duration case by case.
The change rate is calculated by the following formula relative to the change rate before use:
the delta of the product immediately after use T15 min-D0;
delta (difference) using product day 7D 7-D0;
delta (difference) using product day 14D 14-D0;
in the formula, D0-skin parameter base value before the product was applied to the test area.
T15min — immediate product use in the test area, skin parameter values.
D7-skin parameter values on day 7 of product use in test area.
D14 — skin parameter values on day 14 of product use in the test area.
N-number of subjects.
And (3) testing results:
table 1 skin tightness R0 test results
Table 2 skin tightness R0 test results
The statistical method comprises the following steps: the analysis was carried out by the t-test method, and the test level α was 0.05.
The significance labeling method comprises the following steps: (n.s. "indicates no statistical difference, p.gtoreq.0.05; p <0.05 indicates significant difference (" + "indicates 0.01. ltoreq. p < 0.05;" + "indicates 0.001. ltoreq. p < 0.01;" + "indicates p < 0.001).
The number of the used products is 33.
As can be seen from the test results of table 1 and table 2: the skin firmness R0 of the subject was significantly reduced compared to the basal value (p <0.001), with a reduction rate of 14.69%; for 7 days of continuous product samples, the skin firmness R0 of the subjects was significantly reduced compared to the basal value (p <0.001), with a reduction rate of 6.53%; the skin firmness R0 of the subjects was significantly reduced compared to the basal value (p <0.001) with a reduction of 13.82% for 14 days of continuous use of the test product.
Measurement values: the lower the skin firmness R0 value, the more firm the skin.
TABLE 3 skin gloss measurement results
TABLE 4 skin gloss measurement results
The statistical method comprises the following steps: the analysis was carried out by the t-test method, and the test level α was 0.05.
The significance labeling method comprises the following steps: (n.s. "indicates no statistical difference, p.gtoreq.0.05; p <0.05 indicates significant difference (" + "indicates 0.01. ltoreq. p < 0.05;" + "indicates 0.001. ltoreq. p < 0.01;" + "indicates p < 0.001).
The number of the used products is 33.
From the test results of tables 3 and 4, it can be seen that: immediately after the test product sample is used for a single time, the skin glossiness of the test subject is remarkably improved compared with a basic value ((p <0.001), the rate of increase is 10.97 percent, and after the test product sample is continuously used for 7 days, the skin glossiness of the test subject is remarkably improved compared with the basic value (p <0.001), the rate of increase is 15.03 percent, and after the test product sample is continuously used for 14 days, the skin glossiness of the test subject is remarkably improved compared with the basic value (p <0.001), the rate of increase is 22.44 percent.
Measurement values: the greater the skin gloss value, the more glossy the skin.
TABLE 5 Visia-CR skin Brightness ITA DEG value test results
TABLE 6 Visia-CR skin Brightness ITA DEG value test results
The statistical method comprises the following steps: the analysis was carried out by the t-test method, and the test level α was 0.05.
The significance labeling method comprises the following steps: (n.s. "indicates no statistical difference, p.gtoreq.0.05; p <0.05 indicates significant difference (" + "indicates 0.01. ltoreq. p < 0.05;" + "indicates 0.001. ltoreq. p < 0.01;" + "indicates p < 0.001).
The number of the used products is 33.
From the test results of tables 5 and 6, it can be seen that: immediately after the test product sample is used for one time, compared with the Visia-CR skin brightness ITA degree value of the test object, the Visia-CR skin brightness ITA degree value of the test object is obviously increased (p is more than or equal to 0.001 and less than 0.01), and the increase rate is 2.50 percent; the subject's Visia-CR skin brightness ITA ° value was significantly increased compared to the basal value (p <0.001) with a 2.35% increase rate for 7 days with continued use of the test product samples; the subject's Visia-CR skin brightness ITA ° value was significantly elevated compared to the basal value (p <0.001) with a 3.02% increase for 14 days of continuous use of the test product.
Measurement values: the higher the skin brightness ITA DEG value, the brighter and whiter the skin.
TABLE 7 Visia-CR wrinkle area ratio test results
TABLE 8 Visia-CR wrinkle area ratio test results
The statistical method comprises the following steps: the analysis was carried out by the t-test method, and the test level α was 0.05.
The significance labeling method comprises the following steps: (n.s. "indicates no statistical difference, p.gtoreq.0.05; p <0.05 indicates significant difference (" + "indicates 0.01. ltoreq. p < 0.05;" + "indicates 0.001. ltoreq. p < 0.01;" + "indicates p < 0.001).
The number of the used products is 33.
From the test results of tables 5 and 6, it can be seen that: immediately after the single use of the test product sample HY21L988, the Visia-CR wrinkle area ratio of the test subject is remarkably reduced compared with the basic value (p is more than or equal to 0.001 and less than 0.01), and the reduction rate is 8.21 percent; when the test product sample is continuously used for 7 days, the Visia-CR wrinkle area ratio of the test object is remarkably reduced compared with the basic value (p is more than or equal to 0.001 and less than 0.01), and the reduction rate is 11.03 percent; the vicia-CR wrinkle area ratio of the subjects was significantly decreased compared to the basal value (p <0.001) with a 13.74% decrease rate for 14 days of continuous use of the test product.
Measurement values: the lower the skin wrinkle area fraction, the fewer the skin wrinkles.
2. Integrity testing of freeze-dried milk tablets:
the freeze-dried milk tablets of examples 1-6 obtained were visually inspected for integrity and smoothness and the results are shown in Table 9:
TABLE 9
| Integrity of | |
| Example 1 | The block shape is complete and smooth |
| Example 2 | Incomplete, not smooth block shape |
| Example 3 | Incomplete, not smooth block shape |
| Example 4 | Can not be molded |
| Example 5 | Incomplete, not smooth block shape |
| Example 6 | The block is complete and not smooth |
The foregoing examples are merely illustrative and serve to explain some of the features of the method of the present invention. The appended claims are intended to claim as broad a scope as is contemplated, and the examples presented herein are merely illustrative of selected implementations in accordance with all possible combinations of examples. Accordingly, it is applicants' intention that the appended claims are not to be limited by the choice of examples illustrating features of the invention. Also, where numerical ranges are used in the claims, subranges therein are included, and variations in these ranges are also to be construed as possible being covered by the appended claims.
Claims (10)
1. The freeze-dried milk tablet for whitening, repairing and anti-aging is characterized by being prepared from 6-10 parts by weight of excipient, 0.1-2 parts by weight of stabilizer, 0.06-0.2 part by weight of buffering agent, 0.1-2 parts by weight of humectant, 1-5 parts by weight of maltose, 0.1-2 parts by weight of nano microemulsion and 0.1-2 parts by weight of mitochondrial activating factor.
2. The lyophilized milk replacer tablet of claim 1, wherein the excipient is at least one of mannitol, glycine, glucose and sucrose.
3. The lyophilized milk powder for whitening, repairing and anti-aging according to claim 1, wherein the stabilizer is at least one selected from glycine, guar gum, sucrose, lactose and dextran.
4. The lyophilized creamer according to any one of claims 1 to 3, wherein the weight ratio of the stabilizer to the excipient is (0.5-8): 40.
5. the lyophilized creamer according to claim 1, wherein the buffer is at least one selected from acetic acid, succinic acid, glutamic acid, glutaric acid, disodium hydrogen phosphate, and citric acid.
6. The lyophilized creamer according to claim 1, wherein the humectant is at least one selected from 1, 3-butanediol, 1, 2-hexanediol, caprylyl glycol, glycerol, polyglutamic acid, sodium hyaluronate and collagen.
7. The preparation process of the freeze-dried milk powder tablets for whitening, repairing and anti-aging according to any one of claims 1 to 6, characterized by comprising the following steps:
(1) preparation of raw materials: accurately weighing the raw materials of the freeze-dried small milk tablets according to the parts by weight for later use;
(2) preparation of a mold: arranging the mold, washing the mold with pure water, sterilizing and drying to obtain a precise mold;
(3) material preparation and filtration: mixing the freeze-dried small milk tablets with pure water, and filtering to obtain a mixed material A;
(4) precise sterile filtration: performing precise sterile filtration on the mixed material A to obtain a mixed material B;
(5) filling: filling the mixed material B by using a precision mold to obtain a filling material A;
(6) frozen organism dormancy: carrying out frozen biological dormancy treatment on the filling material A;
(7) and (3) low-temperature drying: drying the filling material A after the frozen organisms are dormant at low temperature;
(8) demolding: and demolding the filling material A dried at the low temperature to obtain the freeze-dried small milk tablets.
8. The preparation process of the lyophilized custard tablets for whitening, repairing and anti-aging according to claim 7, wherein the blending and filtering are divided into two steps, the first step is coarse blending and filtering, and the second step is fine blending and filtering.
9. The preparation process of the lyophilized custard tablets for whitening, repairing and anti-aging according to claim 7, wherein a precise flat filter is adopted to perform precise sterile filtration on the mixed materials.
10. The preparation process of the lyophilized custard tablets for whitening, repairing and anti-aging according to claim 7, wherein the freezing way of the frozen biological dormancy is an extremely rapid freezing way.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110671538.5A CN113499279B (en) | 2021-06-17 | 2021-06-17 | Whitening, repairing and anti-aging freeze-dried small milk tablet and preparation process thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110671538.5A CN113499279B (en) | 2021-06-17 | 2021-06-17 | Whitening, repairing and anti-aging freeze-dried small milk tablet and preparation process thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113499279A true CN113499279A (en) | 2021-10-15 |
| CN113499279B CN113499279B (en) | 2023-10-20 |
Family
ID=78010036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110671538.5A Active CN113499279B (en) | 2021-06-17 | 2021-06-17 | Whitening, repairing and anti-aging freeze-dried small milk tablet and preparation process thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113499279B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115777787A (en) * | 2022-11-30 | 2023-03-14 | 内蒙古伊利实业集团股份有限公司 | Milk-containing solid molded article, and method for producing same |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105456050A (en) * | 2015-12-31 | 2016-04-06 | 青岛美博生物技术有限公司 | Freeze-dried powder, essence and skincare set for repairing acne marks and scars |
| CN108836923A (en) * | 2018-06-12 | 2018-11-20 | 成都泽光生物科技有限公司 | A kind of biotic factor attachment suspend mode facial mask production method |
| CN109646320A (en) * | 2019-01-16 | 2019-04-19 | 广州市美夫兰化妆品有限公司 | A kind of skin lightening freeze-dried powder containing oligopeptides and 3-O- ethylascorbyl |
| CN110613628A (en) * | 2019-09-05 | 2019-12-27 | 广州赛莱拉生物基因工程有限公司 | Anti-aging composition, freeze-dried powder containing anti-aging composition and preparation method of freeze-dried powder |
| CN110917150A (en) * | 2019-12-31 | 2020-03-27 | 北京博康健基因科技有限公司 | PTH freeze-dried preparation and preparation method thereof |
| CN111249163A (en) * | 2020-02-28 | 2020-06-09 | 广州市美夫兰化妆品有限公司 | Nourishing and repairing freeze-dried powder and preparation method thereof |
| CN111388346A (en) * | 2020-05-28 | 2020-07-10 | 上海捷丽生物科技有限公司 | Freeze-dried powder live mask with vegetable protein and polypeptide formula and preparation method thereof |
| CN111840201A (en) * | 2020-07-29 | 2020-10-30 | 暨南大学 | Anti-aging and repairing composite preparation containing stem cell factor and preparation method thereof |
| CN112587433A (en) * | 2020-12-30 | 2021-04-02 | 宇肽生物(东莞)有限公司 | Polypeptide freeze-dried tablet and preparation method thereof |
-
2021
- 2021-06-17 CN CN202110671538.5A patent/CN113499279B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105456050A (en) * | 2015-12-31 | 2016-04-06 | 青岛美博生物技术有限公司 | Freeze-dried powder, essence and skincare set for repairing acne marks and scars |
| CN108836923A (en) * | 2018-06-12 | 2018-11-20 | 成都泽光生物科技有限公司 | A kind of biotic factor attachment suspend mode facial mask production method |
| CN109646320A (en) * | 2019-01-16 | 2019-04-19 | 广州市美夫兰化妆品有限公司 | A kind of skin lightening freeze-dried powder containing oligopeptides and 3-O- ethylascorbyl |
| CN110613628A (en) * | 2019-09-05 | 2019-12-27 | 广州赛莱拉生物基因工程有限公司 | Anti-aging composition, freeze-dried powder containing anti-aging composition and preparation method of freeze-dried powder |
| CN110917150A (en) * | 2019-12-31 | 2020-03-27 | 北京博康健基因科技有限公司 | PTH freeze-dried preparation and preparation method thereof |
| CN111249163A (en) * | 2020-02-28 | 2020-06-09 | 广州市美夫兰化妆品有限公司 | Nourishing and repairing freeze-dried powder and preparation method thereof |
| CN111388346A (en) * | 2020-05-28 | 2020-07-10 | 上海捷丽生物科技有限公司 | Freeze-dried powder live mask with vegetable protein and polypeptide formula and preparation method thereof |
| CN111840201A (en) * | 2020-07-29 | 2020-10-30 | 暨南大学 | Anti-aging and repairing composite preparation containing stem cell factor and preparation method thereof |
| CN112587433A (en) * | 2020-12-30 | 2021-04-02 | 宇肽生物(东莞)有限公司 | Polypeptide freeze-dried tablet and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115777787A (en) * | 2022-11-30 | 2023-03-14 | 内蒙古伊利实业集团股份有限公司 | Milk-containing solid molded article, and method for producing same |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113499279B (en) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106214535B (en) | Anti-aging composition containing sponge microneedle capable of activating cells | |
| KR102165567B1 (en) | Cosmetic composition with excellent skin moisturizing effect | |
| CN105997754A (en) | Camellia extraction liquid, and preparation method and application thereof | |
| CN111388346A (en) | Freeze-dried powder live mask with vegetable protein and polypeptide formula and preparation method thereof | |
| CN111991336B (en) | Multi-effect gel essence and preparation method and application thereof | |
| CN113576975B (en) | Easily-absorbed anti-aging composition and preparation method and application thereof | |
| CN112754951A (en) | Cosmetic for repairing skin barrier and preparation method thereof | |
| CN115125153B (en) | Preparation method and application of galactose yeast-like bacteria fermentation product filtrate | |
| CN113842334A (en) | Composition for promoting skin multi-dimensional defense and repair and preparation method thereof | |
| CN110755288A (en) | Cosmetic composition for moisturizing skin and preparation method thereof | |
| CN110664644A (en) | Skin care composition containing folic acid, essence and preparation method thereof | |
| CN113499279A (en) | Freeze-dried milk tablet for whitening, repairing and resisting aging and preparation process thereof | |
| CN113171318A (en) | Freeze-dried powder preparation with moisturizing, whitening, relieving and repairing functions and preparation method thereof | |
| CN113018228B (en) | Anti-aging composition, cream and preparation method thereof | |
| CN113648241A (en) | High-moisture-retention emulsion and preparation method thereof | |
| CN111265454B (en) | Moisture-preserving and water-replenishing anti-aging cosmetic composition | |
| CN112870108A (en) | Composition with anti-aging and moisturizing effects and preparation method and application thereof | |
| CN109125237B (en) | Edible-grade lip-moistening gel and preparation method thereof | |
| CN114886785B (en) | Ternary freeze-dried composition and application thereof in freeze-dried preparation | |
| CN113730289B (en) | Eye and lip care composition with multiple repairing effects and application thereof | |
| CN110101643A (en) | A kind of moisturizing remediation composition and the cosmetics containing the composition | |
| CN113456532A (en) | Zero-pore makeup front cream without silicone oil and preparation method thereof | |
| CN114948800A (en) | Freeze-dried composition containing framework molecules and macromolecular carriers and application thereof | |
| CN108324644A (en) | Skin care compositions based on batyl alcohol stearate and its application | |
| CN115040448A (en) | Skin care product with enhanced anti-aging effect and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240520 Address after: Room 401, Building 4, No. 439 Xinxing Road, Taiping Town, Conghua District, Guangzhou City, Guangdong Province, 510000, Room 401, Building 5 Patentee after: Guangzhou Chenzhuang Biotechnology Co.,Ltd. Country or region after: China Address before: 528500 Workshop on the first floor of building a, No. 6 Xianfeng Road, Mingcheng Town, Gaoming District, Foshan City, Guangdong Province (residence declaration) Patentee before: Guangdong Hongyi Cosmetics Co.,Ltd. Country or region before: China |